-
Posted by
Two Blokes Jun 9 -
Filed in
Stock
-
2 views
The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter.
